What is Strados Labs?
At the core of Strados Labs' operations is the RESP platform, a first-of-its-kind smart sensor system designed to provide clinical-grade monitoring for patients suffering from chronic respiratory diseases. The company has achieved significant regulatory milestones, including FDA Class II 510(k) clearance and a CE Mark, validating the efficacy of its proprietary algorithms. By focusing on high-burden conditions such as asthma, COPD, and infectious respiratory illnesses, the firm addresses a massive unmet need in remote patient monitoring. The company's strategic roadmap involves transitioning from a single-focus respiratory health provider to a broader chronic disease management entity, with plans to integrate heart failure monitoring into its diagnostic suite. This evolution reflects a sophisticated approach to data-driven healthcare, where predictive analytics serve as the foundation for improved patient outcomes and reduced hospital readmission rates.
How much funding has Strados Labs raised?
Strados Labs has raised a total of $6.4M across 3 funding rounds:
Unspecified
$1.8M
Debt
$117K
Other Financing Round
$4.5M
Unspecified (2019): $1.8M with participation from Cathexis Ventures, SOSV, and Ben Franklin Technology Partners Companies
Debt (2021): $117K led by PPP
Other Financing Round (2022): $4.5M supported by Broad Street Angels, Blu Venture Investors, SOSV, Wavemaker Three-Sixty Health, and cultivate
Key Investors in Strados Labs
SOSV
SOSV is a multi-stage venture capital investor that provides intellectual and financial capital to accelerate founders big ideas.
Wavemaker Three-Sixty Health
Wavemaker Three-Sixty Health is a leading U.S. venture capital fund that focuses exclusively on early-stage healthcare startups, investing in promising companies across North America.
Blu Venture Investors
Blu Ventures is an early-stage venture capital fund specializing in cybersecurity and technology investments, founded by former operators with extensive experience in scaling companies.
What's next for Strados Labs?
With the recent influx of capital, Strados Labs is well-positioned to scale its operations and broaden its clinical footprint. The strategic focus for the coming fiscal periods involves the aggressive rollout of the RESP platform across diverse healthcare settings, alongside the development of a robust pipeline of sensor technologies. As the company expands its diagnostic capabilities to include heart failure, it will likely seek further partnerships with healthcare providers and insurance networks to integrate its solutions into standard care pathways. The transition from a venture-backed startup to a mature medical technology provider will require sustained investment in clinical validation and market penetration, ensuring that their predictive algorithms remain at the forefront of the digital health revolution.
See full Strados Labs company page
